A Prospective, Open, Multi-Center, Controlled Study to Evaluate the Safety, Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Atrium; Fibrillation
- Sponsor
- CardiacSense Ltd.
- Enrollment
- 53
- Locations
- 2
- Primary Endpoint
- CardicacSense1 atrial fibrillation detection rate
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
A Prospective, Open, Multi-Center, Controlled Study to Evaluate the Safety, Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation.
The clinical study is intended to establish the efficacy and safety of the CardiacSense1 wearable device intended to monitor and detect heart arrhythmia, specifically atrial fibrillation (A-Fib) based on a comparison to a control device, which is an off-the-shelf cleared Holter ECG device
Detailed Description
The clinical study is intended to establish the efficacy and safety of the CardiacSense1 wearable device intended to monitor and detect heart arrhythmia, specifically atrial fibrillation (A-Fib). Study design as as follows: 100 subjects, 50 (at least 30% of each gender) with A-fib and 50 without (at least 30% of each gender). All subjects will be measured during at least 24 hours. Primary endpoint - A-Fib detection Control: Holter device will be the reference For PPG analysis, each one hour will be considered as an event: If A-Fib is present for more than accumulated 5 minutes in that specific hour then it shall be considered an "A-Fib hour" If A-fib was present for less than accumulated 5 minutes then it shall be considered a "Non-A-Fib hour". For ECG analysis, each measurement of between 1-3 minutes will be considered an event. If A-Fib is present at that specific measurement, then it shall be considered an "A-Fib event" If A-fib was not present at that specific measurement, then it shall be considered a "Non-A-Fib hour". Sensitivity (true positive) is defined as the percentage of Holter defined "A-fib hours"/"A-Fib event" found by PPG/ECG. The asked sensitivity is 90%. Specificity (true negative) is defined as the percentage of Holter defined "Non-A-fib hours"/"A-Fib event" found by PPG/ECG. The required specificity is 90%.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age of eighteen (18) year and above
- •Diagnosed with atrial fibrilation (Permanent of persistent), or healthy participants able to and willing to sign the informed consent form For control group-no known cardiac problems
Exclusion Criteria
- •Subjects who are currently enrolled in another clinical investigation in which the intervention might compromise the safety of the subject's participation in this study.
- •Subjects with low perfusion as indicated by the watch
- •Women who are pregnant or breastfeeding
Outcomes
Primary Outcomes
CardicacSense1 atrial fibrillation detection rate
Time Frame: 24 to 48 hours
Comparison of the number of atrial fibrillation sessions detected by reference comparing to PPG and ECG sensors in CardiacSense device.
Safety of CardicacSense1
Time Frame: 24 to 48 hours
Incidence and severity of device related Adverse Events
Secondary Outcomes
- Usability(24 to 48 hours)